Next 10 |
home / stock / acog:cc / acog:cc news
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reporte...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reporte...
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held March 7th are now available for online viewing. This event was sponsored by Zacks Smal...
NEW YORK, March 05, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the agenda for the Life Science Investor Forum to be held March 7 th . This event is sponsored by Zacks Small-Cap Research. Individual investors, inst...
VANCOUVER, British Columbia, March 01, 2024 (GLOBE NEWSWIRE) -- Alpha Cognition, Inc. (CSE: ACOG)(OTCQB: ACOGF) , a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today an...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition” (ACI), or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that it has filed a new composition-of-matter p...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders provides a business update on it’s ALPHA-1062 NDA filing for U.S. approval of mild-to-moderate Alzheimer’s disease, commercializa...
Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“ Alpha Cognition ” or the “ Company ”) announces that it has completed a final closing pursuant to its previously announced private placement of units of the Company. Pursuant to the final closing, the Company is...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (Alpha Cognition “ACI”, or the “Company”), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, is pleased to announce that the U.S. Food and Drug Administration (FDA) ...
Alpha Cognition Inc. (CSE: ACOG, OTCQB: ACOGF) (“ Alpha Cognition ” or the “ Company ”) announces that it has amended the terms of its previously announced private placement offering of up to US$6.5 million of units at a price of US$0.22 per unit. Each unit wil...
News, Short Squeeze, Breakout and More Instantly...
Alpha Cognition Inc. Company Name:
ACOG:CC Stock Symbol:
TSXVC Market:
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition”, or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reporte...
Alpha Cognition Inc. (CSE: ACOG) (OTCQB: ACOGF) (“Alpha Cognition,” or the “Company”), a biopharmaceutical company committed to developing novel therapies with the potential to transform the lives of people with debilitating neurodegenerative disorders, today reporte...
NEW YORK, March 08, 2024 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Science Virtual Investor Forum held March 7th are now available for online viewing. This event was sponsored by Zacks Smal...